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Background—Treatment of in-stent restenosis presents a critical limitation of intracoronary stent implantation. Ionizing
radiation has been shown to decrease neointimal formation within stents in animal models and in initial clinical trials.
We studied the effects of intracoronary g-radiation therapy versus placebo on the clinical and angiographic outcomes
of patients with in-stent restenosis.
Methods and Results—One hundred thirty patients with in-stent restenosis underwent successful coronary intervention and
were then blindly randomized to receive either intracoronary g-radiation with 192Ir (15 Gy) or placebo. Four independent
core laboratories blinded to the treatment protocol analyzed the angiographic and intravascular ultrasound end points of
restenosis. Procedural success and in-hospital and 30-day complications were similar among the groups. At 6 months,
patients assigned to radiation therapy required less target lesion revascularization and target vessel revascularization (9
[13.8%] and 17 [26.2%], respectively) compared with patients assigned to placebo (41 [63.1%, P50.0001] and 44
[67.7%, P50.0001], respectively). Binary angiographic restenosis was lower in the irradiated group (19% versus 58%
for placebo, P50.001). Freedom from major cardiac events was lower in the radiation group (29.2% versus 67.7% for
placebo, P,0.001).
Conclusions—Intracoronary g-radiation used as adjunct therapy for patients with in-stent restenosis significantly reduces
both angiographic and clinical restenosis. (Circulation. 2000;101:2165-2171.)
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In-stent restenosis after successful intracoronary stentimplantation has become a major clinical problem. It
occurs in 7% to 37% of patients who undergo stent
implantation and is dependent on patient characteristics,
lesion morphology, and procedural technique.1–3 Serial
intravascular ultrasound studies have demonstrated that
in-stent restenosis results primarily from neointimal tissue
proliferation distributed either focally or diffusely over the
entire length of the stent.4,5 The recurrence rate after
treatment for in-stent restenosis varies among reported
series but remains high (.30%) regardless of treatment
modalities, including balloon angioplasty,6 – 8 rotational
atherectomy,9 excimer laser ablation,10 and repeat stent-
ing.11,12 The diffuse pattern of in-stent restenosis (.10 mm
length) is associated with even higher rates of recurrence
and presents a therapeutic challenge.11
See p 2130
Studies with intracoronary ionizing radiation using g-and
b-emitters after intervention delivered by catheter-based sys-
tems have demonstrated a reduction in neointimal formation
in porcine coronary models.13–16 Clinical feasibility studies in
patients have suggested reduced postangioplasty restenosis
after g- and b-radiation therapy.12,17,18 In the present study,
we report the results from a prospective, randomized, double-
blind trial examining the effectiveness and safety of intracor-
onary catheter-based g-radiation therapy compared with pla-
cebo as an alternative for patients requiring treatment for
in-stent restenosis.
Methods
This clinical trial was sponsored by an Investigational Device
Exemption granted by the Food and Drug Administration to the
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principal investigator (R.W.) and approved by the Institutional
Review Board and the Radiation Safety Committee at the Washing-
ton Hospital Center. The study was monitored by an external data
and safety-monitoring board, which met at 1, 3, 6, and 12 months
after the initiation of the study. Informed consent was obtained from
all patients before study enrollment.
Selection of Patients
The study population consisted of 130 consecutive patients, 30 to 80
years of age, with previous intracoronary stent implantation in native
coronaries (n5100) or in aortocoronary venous bypass grafts
(n530). Patients presented with symptoms of angina and angio-
graphic evidence of in-stent restenosis. Angiographic entry criteria
included diameter stenosis $50% within the stent treatment site in
vessels that were 3.0 to 5.0 mm in diameter and had a lesion length
,47 mm in patients who underwent successful (,30% residual
stenosis without complications) angioplasty with the use of (alone or
in combination) balloons, ablative devices, or additional stents. Main
exclusion criteria were patients with recent (,72-hour) acute myo-
cardial infarction, ejection fraction ,20%, prior irradiation treatment
to the chest, evidence of angiographic thrombus, and multiple lesions
in the same vessel.
Study Protocol
Before intervention, an angiogram and an intravascular ultrasound
study (3.2F catheter with motorized pullback at 0.5 mm/s, Cardio-
vascular Imaging Systems) were performed to determine lesion
length and vessel size. Focal lesions (,10-mm length) were treated
with balloon dilatation, and diffuse lesions ($10-mm length) under-
went initial ablation with use of either an excimer laser or rotational
atherectomy, which was then followed by balloon dilatation. Addi-
tional stents were used, as required, to optimize final angiographic
results or to cover unstented portions of the lesion (including edge
dissection). In preparation for radiation treatment, the patient was
sedated, and the activated clotting time was maintained at .300
seconds with intravenous heparin. Two leaded shields (2-in thick-
ness) were placed in proximity on either side of the table to minimize
radiation exposure in the room. A closed end-lumen 5.0F noncen-
tered catheter (Medtronic Vascular Interventional) was inserted into
the vessel and positioned to span the lesion length. The patient was
randomly assigned to receive a nylon ribbon (0.0030-in diameter)
containing different seed trains of either placebo or 192Ir (Best
Medical International). The radiation oncologist hand-loaded the
ribbon from a lead container positioned on a cart next to the table
into the closed end-lumen catheter. The cardiologist documented by
angiography accurate positioning of the source to cover the entire
lesion site plus at least a 4-mm overlap of normal segments on each
end. All catheterization laboratory personnel left the room during the
dwell period for active source radiation or placebo treatment, except
for the radiation safety officer, who measured exposure rates at
various locations. Patients were carefully monitored from the control
room adjacent to the catheterization laboratory. At the end of the
treatment, the radiation oncologist entered to the room and retrieved
the ribbon into the shielded lead container, and the medical personnel
returned once the radiation exposure reached background values. A
final angiogram and an intravascular ultrasound study were per-
formed. If significant reduction in luminal dimensions was observed,
further balloon dilatation or stent implantation was used to obtain
optimal final results. Patients received routine postangioplasty care,
including treatment with ticlopidine (250 mg orally, twice daily for
1 month.), regardless of whether additional stents were implanted.
Radiation Details and Dosimetry
The prescribed dose was 15 Gy to a distance of 2.0 mm from the
surface of the source for vessels between 3.0 and 4.0 mm or 15 Gy
to a distance of 2.4 mm for vessels .4.0 mm in diameter. Different
trains of seeds were used (5, 9, or 13 to cover total lengths of 19, 36,
and 51 mm, respectively). All seeds were equal in length (3 mm
separated with a 1-mm space), with a mean specific activity of
25.363.5 mCi. Monte Carlo calculations detected maximum dose to
the near wall of #45 Gy, whereas the minimum dose to the far wall
was $7.3 Gy.
End Points and Follow-Up
The primary clinical end point was the cumulative composite
outcome defined as the occurrence of death, myocardial infarction,
and repeat TLR at 6 months. Important secondary angiographic end
points at 6 months were restenosis (defined as diameter stenosis
$50%), the magnitude of late loss, and the late loss index. All
patients had clinical follow-up evaluations at 1, 3, 6, and 12 months
after the procedure. At 6 months, repeat coronary angiography and
intravascular ultrasound studies were performed.
Angiographic Analysis
Quantitative coronary angiographic analysis was performed indepen-
dently by 2 core angiographic laboratories blinded to the treatment
assignment. The Thoraxcenter laboratory used the CASS-II system
(Pie Medical), and the Washington Hospital Center laboratory used
the CMS-GFT system (Medis). Angiographic binary restenosis at
follow-up (angiograms 4 to 8 months after treatment) was defined as
$50% diameter narrowing within the stent and in the segment
including the stent plus its edges (within 5 mm). A luminal diameter
of 0 mm was imputed in the presence of a total occlusion at baseline
or at follow-up. Acute gain (in millimeters) was defined as the
change in the stent MLD from baseline to the final procedural
angiogram. Late loss (in millimeters) was defined as the change in
stent MLD from the final to the follow-up angiogram, and the
arithmetic loss index within the stent was defined as the ratio of late
loss to acute gain.
Intravascular Ultrasound Analysis
Two independent core laboratories, at Stanford University and at the
Washington Hospital Center, blinded to the treatment protocols
independently analyzed the procedural and follow-up studies. Both
procedural and follow-up studies were analyzed at every 1-mm axial
length, including the stented segment and a 5-mm length proximal
and distal to the stent edges of the stent. By use of computerized
planimetry, the stent and luminal cross-sectional areas of each image
slice were traced manually, and the cross-sectional area of intimal
hyperplasia (tissue volume) present within the stent on each image
slice was calculated. Intimal plaque volumes were calculated by
Simpson’s rule. The growth of tissue within the stent struts at
follow-up was calculated as the intimal area (or volume) at follow-up
minus the intimal area (or volume) immediately after the procedure.
Statistical Analysis
The target sample size of 130 patients (with previous stent implan-
tation in 100 native coronaries and 30 saphenous vein grafts with
separate randomization) was determined (80% power and 95%
confidence) to demonstrate a 50% reduction in the composite clinical
end point. Data were recorded prospectively and were forwarded to
the data-coordinating center at the Washington Hospital Center. All
clinical events were independently adjudicated by an external com-
mittee that reviewed source-documented data in a blinded fashion.
Outcomes were analyzed according to the “intention-to-treat”
principle. Results are expressed as mean6SD. The Student t test was
used to compare continuous variables; the x2 test or Fisher exact test
was used to compare categorical values. The TLR, TVR, and the
composite clinical end point were analyzed by use of Kaplan-Meier
survival curves, with differences between the 2 treatment groups
compared by the log-rank test. A value of P,0.05 was considered
significant.
Results
Between February 1997 and January 1998, 130 patients with
in-stent restenosis were enrolled. Baseline clinical and angio-
graphic characteristics of the treatment groups are shown in
Tables 1 and 2, respectively. Overall, 48% had diabetes, 60%
had previous treatment of in-stent restenosis, and 75% had a
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diffuse pattern of in-stent restenosis (lesion length .10 mm)
with a mean lesion length of 28.8612.4 mm.
Procedural Details and Early Outcome
The distribution of devices and number of seeds used are
shown in Table 2. Balloon angioplasty alone was used in only
14 (10.7%) lesions. Atheroablative devices were most fre-
quently used: rotational atherectomy in 60% of native coro-
naries and excimer laser in 90% of vein grafts. Restenting
was performed in 46 (35.4%) lesions because of either tissue
prolapse (in 26 lesions) or the necessity to cover edge
dissections (in the remaining 20 lesions). Most lesions were
treated with a 13-seed ribbon with an average of 10.962.7
seeds per lesion to cover an average length of
41.31611.8 mm. The dwell time was 22.065.3 minutes to
deliver the prescribed dose and was tolerated well by most of
the patients. However, 4 patients (2 from each group),
including 1 from the placebo group who did not complete the
treatment because of persistent ischemia, required dose frac-
tionation. Radiation exposure rates during treatment were as
follows: patient’s chest, 5.060.2 R/h; catheterization table,
6506120 mR/h; 1 m from the table, 107635 mR/h; behind
the leaded shield, 53624 mR/h; and at the control room,
0.2360.06 mR/h (background levels). All procedures were
free of major adverse events, and only 2 patients required
vascular access site repair. There were no deaths, subacute
closure, or Q-wave myocardial infarctions in hospital or after
30 days. Creatine kinase-MB elevations .3 times baseline
were detected in 11% of the irradiated group versus 8% of the
placebo group (P5NS).
Angiographic Results
Follow-up angiography was performed at a mean of 188659
days in 59 patients (90.7%) from the irradiated group and at
a mean of 151671 days in 59 patients (90.7%) from the
placebo group. The quantitative angiographic results of both
core laboratories were similar (Table 3). The cumulative
distribution curves for minimum luminal diameter (MLD) are
shown in Figure 1. Compared with placebo, radiation therapy
resulted in a significant reduction in restenosis both within
the stent (67% reduction, P,0.001) and in the segment
including the stent edges (63% reduction, P50.001). The
radioactive ribbon/lesion length ratio was 0.92; the placebo
ribbon/lesion length ratio was 0.96. In 72% of patients with
edge effect, the source length did not cover the entire treated
lesion length. The greatest treatment benefit was within the
stent; a higher late loss was observed in the segment includ-
ing the stent edges (0.3660.74) versus the segment only
including the stent (0.2260.84, P50.04). The predominant
angiographic pattern of restenosis in the irradiated group was
at the edges, with a mean lesion length of 1063.1 mm,
compared with a diffuse pattern of recurrence in the placebo
group, with a mean lesion length of 21610.2 mm (P50.005).
TABLE 1. Baseline Clinical Characteristics of 130 Patients
With In-Stent Restenosis Assigned to Radiation Therapy (192Ir)
or Placebo
Characteristic
192Ir Group
(n565)
Placebo Group
(n565)
Age, y 63.2610.9 62.3610.2
Male sex, % 66 72
Hyperlipidemia, % 83 89
Hypertension, % 72 68
Diabetes mellitus, % 39 45
Previous myocardial infarction, % 45 45
Unstable angina, % 82 68
Multivessel disease, % 65 56
Previous CABG, % 57 51
Previous PTCA, % 100 100
Previous in-stent restenosis, % 47 39
Ejection fraction 0.4760.11 0.5060.11
Values are mean6SD or percentages of patients. Values of P, calculated to
the differences between placebo and 192Ir, were not significant.
TABLE 2. Angiographic and Procedural Characteristics
According to Study Groups
Variable
192Ir Group
(n565)
Placebo Group
(n565)
Target vessels
Left main, % 5 3
LAD 28 25
LCx 23 23
RCA 21 26
SVG 23 23
Lesions
Location
Ostial, % 23 28
Proximal, % 28 28
Mid, % 38 32
Distal, % 11 12
Mean lesion length, mm 28.8612.4 26.7611.3
Lesion length .10 mm, % 73 75
Total occlusion, % 6 8
Bifurcation, % 35 34
Device used, %
Balloon alone 9 12
Rotational atherectomy 45 48
Laser angioplasty 35 34
Stent alone 11 6
Additional stents 40 31
Seeds
Length
5 seeds (19 mm), % 8 14
9 seeds (35 mm), % 35 34
13 seeds (51 mm), % 57 52
Delivery success, % 100 98.5
Dwell time, min 22.666.7 21.363.4
Values are mean6SD or percentages of patients. LAD indicates left anterior
descending coronary artery; LCx, left circumflex coronary artery; RCA, right
coronary artery; and SVG, saphenous vein graft.
Values of P, calculated to the differences between placebo and 192Ir, were
not significant.
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There was no evidence of perforation or aneurysm formation
in the irradiated group.
Intravascular Ultrasound Results
The intravascular ultrasound results analyzed by 2 indepen-
dent core laboratories confirmed the angiographic results
(Table 4). In 25 (53.2%) of the lesions from the irradiated
group, there was an increase in luminal dimensions and a
regression in the neointimal tissue at 6 months. The neointi-
mal tissue volume measured 59.6640.3 mm3 after radiation
and 57.4636.3 mm3 at follow-up. An example of tissue
regression is shown in (Figure 2). None of the patients in the
placebo group showed an increase in luminal dimensions or a
regression of tissue volume; the posttreatment tissue volume
increased from 72.8672.7 to 132.86137.4 mm3 at follow-up.
Late Clinical Events
Clinical follow-up at 30 days, 6 months, and 12 months was
obtained in all patients. Event-free survival (freedom from
death, myocardial infarction, and repeat revascularization)
was greater for patients assigned to radiation compared with
placebo (Table 5). Late thrombosis was associated with
non–Q-wave myocardial infarction in 5 of 6 patients from the
irradiated group and in 2 of 2 patients from the control group.
At 6 months, freedom from target lesion revascularization
(TLR) and target vessel revascularization (TVR) was 86%
and 74%, respectively, in the irradiated group versus 37% and
32%, respectively, in the placebo group (P50.001). Between
6 and 12 months, there was an increase of 9.3% in TLR and
7.6% in TVR in the irradiated group only (Table 5, Figure 3).
A multiple logistic regression analysis indicated that radi-
ation therapy was the only predictor of freedom from angio-
graphic or clinical restenosis (P50.0001). Subanalysis of
patients with native coronaries showed similarly reduced
TVR in the irradiated (16%) versus placebo (66%) patients,
with a reduction of major cardiac events (32% versus 72%,
both P50.001). In the 30 vein graft patients, there was also a
TABLE 3. Angiographic Results at 6 Months
Variable
WHC Core Lab Thoraxcenter Core Lab
P
192Ir
(n559)
Placebo
(n559)
192Ir
(n559)
Placebo
(n559)
At baseline
Reference vessel, mm 2.7160.53 2.7260.56 NA NA 0.9
MLD, mm 0.9460.42 0.8160.42 NA NA 0.07
Degree of stenosis, % 65614 70614 NA NA 0.06
After procedure
Reference vessel, mm 2.7960.50 2.8560.50 2.8760.52 2.8960.58 0.54
MLD, mm 2.2360.52 2.2560.5 1.9460.51 1.9660.50 0.84
Degree of stenosis, % 19615 20615 2469 2569 0.69
At 6 mo
Reference vessel, mm 2.9060.52 2.8760.58 2.5260.85 2.3260.82 0.79
MLD, mm 2.0360.93 1.2460.77 1.5760.73 1.0660.58 0.0001
Degree of stenosis, % 30630 57621 37622 52621 0.0001
Changes in MLD
Immediate luminal gain, mm 1.2960.53 1.4460.53 NA NA 0.12
Late luminal loss, mm 0.2260.84 1.0060.69 0.3860.67 0.8960.67 ,0.0001
Late loss index, mm 0.1660.73 0.7060.46 NA NA 0.0001
Restenosis of stent only, % of patients 19 58 16 48 0.0001
Restenosis of stent and edges, % of patients 22 60 NA NA 0.0001
Values are mean6SD or percentages of patients. WHC indicates Washington Hospital Center; NA, not applicable. Values of P were
calculated to the differences between placebo and 192Ir for the WHC core lab. There were no statistically significant differences
between the laboratories.
Figure 1. Cumulative distribution curves for MLD before and
immediately after intervention and at follow-up in patients with
in-stent restenosis assigned either to placebo or g-radiation with
192Ir. Curves are similar before and after procedure for both
treatment groups. Curve at follow-up for placebo group is
shifted to the left; curve for irradiated group overlaps postproce-
dure curves.
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lower incidence of TVR in the irradiated group (6.7%) versus
the placebo group (53.3%, P50.014) and fewer overall major
cardiac events in the irradiated group (20%) versus the
placebo group (53.3%, P50.058).
Discussion
Intracoronary stenting involves .60% of all coronary inter-
ventions performed today. As a result, in-stent restenosis,
especially in its diffuse pattern, remains a serious medical
problem. The present study demonstrates that intracoronary
g-radiation, as adjunct therapy to intervention for the treat-
ment of in-stent restenosis, is feasible, effective, and safe
without periprocedural adverse events compared with pla-
cebo. The patients in the present study represent the “real
world” of severe in-stent restenosis, the “frequent fliers” of
coronary intervention. The high-risk patient profiles and the
nature of the disease may explain the high event rates for the
overall cohort, with a mortality of 5.2% at 6 months.
Nevertheless, radiation therapy showed a dramatic reduction
(.60%) in clinical restenosis, which was supported by
angiographic and intravascular ultrasound indices. Several
feasibility studies using intracoronary ionizing radiation after
angioplasty or stenting have been reported. Among these, 2
studies used g-radiation: a registry for de novo lesions17 and
a small randomized study for patients with restenosis who
were treated with stenting.12 Both studies reported a reduction
in the angiographic late loss and restenosis frequency asso-
ciated with the use of 192Ir. Lower angiographic indices of
restenosis were also reported with b-emitters, such as stron-
tium Sr 90/yttrium Y 9018 and phosphorus P 32. However,
none of these studies specifically targeted a patient popula-
tion of in-stent restenosis. The present study demonstrates an
important therapeutic application for intracoronary
g-radiation, which specifically addresses a disease state
(diffuse in-stent restenosis) that currently lacks acceptable
alternative treatments. The angiographic analysis demon-
strated a striking reduction in late loss for the irradiated group
compared with placebo group, and in .50% of irradiated
patients, the MLD at follow-up was unchanged. These find-
ings were corroborated by the ultrasound analysis, which
showed convincing evidence of intimal hyperplasia regres-
sion after radiation. Interestingly, the late loss was found to
be less at the center of the lesion compared with the edges,
where catheter placement was less precise, and there was a
dose drop-off by as much as 30%. These findings support the
importance of accurate dosimetry and suggest that better
coverage of the lesion by treating longer margins may further
reduce the restenosis rate at the edges. Overall, the dosimetry
strategy for the present study was effective despite the lack of
centering of the radiation catheter and without the use of
intravascular ultrasound imaging to determine minimum and
maximum doses to the tunica media as previously proposed
TABLE 4. Intravascular Ultrasound Results at 6 Months
Variable
WHC Core Lab Stanford Core Lab
P
192Ir
(n554)
Placebo
(n557)
192Ir
(n537)
Placebo
(n538)
Change in mean stent
CSA, mm2
0.1960.59 0.0760.57 NA NA 0.30
Change in mean luminal
area, mm2
0.6161.64 1.9761.58 0.1860.91 1.8761.75 0.0004
Change in mean minimal
luminal CSA, mm2
0.3861.94 1.9161.58 0.1360.75 2.3161.54 ,0.0001
Change in volume of tissue
growth, mm3
3.13638.43 54.98660.13 2.16619.17 50.0669.3 ,0.0001
Decrease in mean luminal
volume, mm3
7.87642.08 56.37665.19 NA NA ,0.0001
Values are mean6SD. Values of P were calculated to the differences between placebo and 192Ir for the WHC core
lab. CSA indicates cross-sectional area. There were no statistically significant differences between the laboratories.
TABLE 5. Major Cardiac Events at 6 and 12 Months After Procedure
Event
192Ir (n565) Placebo (n565)
P6 mo 12 mo 6 mo 12 mo
Death 3 (4.6) 4 (6.2) 4 (6.2) 4 (6.2) NS
Q-wave MI 0 0 0 0 z z z
Non–Q-wave MI 6 (9.2) 6 (9.2) 5 (7.7) 6 (9.2) NS
Late thrombosis 5 (7.6) 6 (9.2) 2 (3.5) 2 (3.5) NS
TLR 9 (13.8) 15 (23.0) 41 (63.1) 41 (63.1) ,0.001
TVR 17 (26.1) 22 (33.8) 44 (67.6) 44 (67.6) ,0.001
Death, Q-wave MI, and TVR 19 (29.2) 23 (35.3) 44 (67.6) 44 (67.6) ,0.001
Values are number of patients, with percentages for that group in parentheses. NS indicates not
significant.
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in the Scripps Coronary Radiation to Inhibit Intimal Prolif-
eration Post Stenting (SCRIPPS) study.12 The lack of early
and late adverse events supports the notion that the therapeu-
tic and toxic windows for 192Ir are sufficiently broad to
accommodate a simple fixed dosimetry scheme. The late
thrombosis seen more in the irradiated group was reported in
other radiation trials using b-emitters19,20 and seems to be a
complication of the radiation therapy that will require further
investigation and treatment strategy, such as prolonged anti-
platelet therapy.20
An important observation is the increase in the revascular-
ization rate between 6 and 12 months in the irradiated group
only. Although these changes do not affect the clinical benefit
observed in the treated versus placebo groups, they do
suggest that radiation may delay in part the biological
processes and that a late “catch-up” phenomena or late
thrombosis will ultimately minimize the long-term benefit of
radiation. In addition, caution should be observed concerning
the potential risk of late effects of radiation, which may occur
10 years after treatment, as previously reported with the use
of external radiation.21
All clinical interventional practitioners agree that in-stent
restenosis is a compelling dilemma that mandates an imme-
diate solution. On the basis of the encouraging and convinc-
ing results of the present study, we submit that intracoronary
g-radiation using 192Ir is an important and viable therapeutic
option for patients who suffer from recurrence of in-stent
restenosis.
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